Press Releases

(San Antonio, TX, January 31, 2007) – Seno Medical Instruments, Inc., a company engaged in the development of medical devices, announced the completion during December 2006 of its Series A Preferred Stock offering.  The San Antonio-based company received aggregate proceeds in the amount of $6.0 million from the offering.  This funding allowed the company to start pursuing the development and commercialization of its innovative, patented opto-acoustic technology.

The platform technology, which combines light and sound to produce high contrast images for cancer detection, has a multitude of potential applications. Initial applications will target the research and breast cancer markets.  The first clinical applications, breast cancer diagnosis and screening, will target a market estimated to be $5.9B (North America only).  Future applications include ovarian, prostate, colorectal, bladder, and melanoma cancers, as well as a multitude of other non-cancer applications.

The company’s Chief Executive Officer, Janet Campbell, is one of the first female CEOs in the breast cancer imaging industry.  Ms. Campbell stated, “This funding milestone is cause for celebration among company founders and investors.  The prominence of our Series A investors in the medical field is yet another validation of this potentially ground-breaking technology.”

SAN ANTONIO, TEXAS — August 4, 2006 – Seno Medical Instruments, Inc., a San Antonio medical device company specializing in the early detection of cancer, announced today Joseph C. McNay of Boston, Massachusetts will join its Board of Directors. McNay joins Seno Medical Instruments at an exciting time for the company. Seno recently announced it has received $3 (M) million dollars in funding to launch commercial operations. This funding will allow the company to further develop patented laser optoacoustic breast imaging technology for commercial use by doctors and hospitals around the world.

McNay currently serves as President of the Boston Securities Analyst Society (BSAS), a non-profit association founded as a forum for the exchange of information in the investment community. It currently serves over 4,500 members. McNay is also the Chairman and Chief Investment Officer and Managing Principal of Essex Investment Management Company, LLC. Prior to founding Essex in 1976, he was Executive Vice President and Director of Endowment Management and Research Corp. for nine years.

McNay, esteemed in the global business community for his investment expertise, is also well-regarded as a leader in the medical community. He currently serves as a Trustee of the Dana Farber Cancer Institute and on the Investment Committee of Children’s Hospital Boston. McNay is head of the Advisory Committee for the Juda Folkman Foundation, which supports Dr. Juda Folkman for his research at Children’s Hospital Boston. In addition to serving on Seno Medical’s Board of Directors, he will continue to serve on the Board of Directors at the biotechnology company, ReGenRx Biopharmaceuticals, Inc.

McNay is admired for sharing his investment knowledge as a Trustee of National Public Radio, the Boston Ballet and the Woods Hole Oceanographic Institution. He is a Yale University graduate with an M.B.A. from the Wharton School of Finance.

“As we persist in growing Seno Medical Instruments, we continue to look for outstanding people like Joe McNay to bring levels of expertise we can depend on to reach our goals,” said Janet Campbell, Seno Medical CEO. “We anticipate Joe’s extensive experience in both investment and medical arenas to positively impact our future growth.”

(San Antonio, TX, June 29, 2006) – Seno Medical Instruments, Inc. is one step closer to moving breakthrough breast cancer diagnostic technology to the global marketplace. The San Antonio-based medical device company announced it has received more than $3 (M) dollars to launch commercial operations. This funding will allow the company to further develop patented laser optoacoustic breast imaging technology for commercial use by doctors and hospitals around the world. The target market for the breast cancer diagnostic technology is estimated to be $5.9 (B) billion dollars in North America alone.

Validation of the science has been confirmed repeatedly through peer review and more than $13 (M) million dollars in funding from the National Institutes of Health, the Department of Defense and the National Cancer Institute. The NCI recently awarded Seno Medical’s development partner, Fairway Medical Technologies, Inc., with a $1.1 (M) million dollar grant to expand the technology for prostate cancer applications.

Seno Medical’s development partner, Fairway Medical Technologies has been collaborating with the University of Texas Medical Branch in Galveston to further develop its proof-of -concept. The platform technology, which fuses light and ultrasound to create strong contrast between normal and cancerous tissues, has a multitude of potential applications. They include the diagnosis of ovarian, prostate, colorectal, bladder, and melanoma cancers. The technology will also have cardiovascular applications.

Seno’s CEO, Janet Campbell is one of the first woman CEO’s in the breast cancer imaging industry. She says, “More than 1.2 million women and men around the world will be diagnosed with breast cancer according to the World Health Organization. Our technology has the ability to detect cancer in its earliest stages without breast compression or exposure to x-ray. We are tremendously excited about the opportunity to bring this technology to patients everywhere.”

Ron Branstetter, President and COO of Seno Medical said, “I am excited about the quality of the technical and business teams we have assembled so that we may soon offer this state-of-the-art technology to physicians, hospitals and mammography centers.”

Ms. Campbell most recently served as President and COO of InforMedix, Inc, where she oversaw the company’s IPO and successfully hired the team that launched the company’s first commercial product. She also served as Chairman of the Board of Directors for Vascular Genetics, Inc. Ms. Campbell received her BA from the University of Missouri and her MBA from The Johns Hopkins University.

Seno is also pleased to announce that Dr. Robert Kramer, a recent nominee for surgeon general and a founding Board Member of the Susan G. Komen Foundation, has accepted the nomination to lead the Scientific Advisory Board. The Scientific Advisory Board will be comprised of experts in the field of breast cancer and will be actively involved in the company.

If you would like to know more about this breakthrough technology or would like to interview Seno Medical CEO, Janet Campbell, please contact Liz Bradford at 214-202-8830.